10/671,711

FEB 0 6 2004 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Banholzer, R. et al) Art Unit: 1625

U.S. Appln. No. : 10/23/2003) Examiner: J. L. Coppins

Confirmation No.: To Be Accorded U.S. Filing Date: 10/23/2003

Title of Invention: Crystalline Tiotropium Bromide Monohydrate, Processes for the

Preparation Thereof, and Pharmaceutical Compositions

Attny. Docket No.: 1/1148-2-C2

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

February 4, 2004

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents listed herein and on the attached PTO-1449 form and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies of the citations listed on the PTO-1449 form are filed in US Application No. 09/961,822, filed on September 24, 2001, Banholzer, R. et al (Attorney Docket No. 1/1148) and in US Application No. 10/354,521, filed on January 30, 2003, Banholzer, R. et al (Attorney Docket No. 1/1148-1-C1).

\boxtimes	1.97(b).	This Statement is being filed: i) within three (3) months of the filing
date of	`a national app	dication other than a continued prosecution application under 33 C.F.R.
§1.53 ((d); ii) within the	hree (3) months of the date of entry of the national stage as set forth in
37 C.F	.R. §1.491 in a	in international application; iii) before the mailing of a first Office action
		pefore the mailing of a first Office action after the filing of a request for
continu	ied examinatio	on under 37 C.F.R. §1.114.

1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

	A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
ent as s). This Statement is being filed after the period specified in 37 C.F.R. n or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.97(e).
counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a rpart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
foreign making inform C.F.R.	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 §1.56(c) more than three (3) months prior to the filing of the instant ation disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated

in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

 \boxtimes The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Patent Department

Ridgefield, CT 06877

Date: February 4, 2004

Tel: (203) 798-5285

Boehringer Ingelheim Corp.

900 Ridgebury Road, P.O. Box 368

Respectfully submitted,

michael P. Monis

Michael P. Morris

Attorney for Applicant(s)

Reg. No. 34,513

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on February 4, 2004.

Michael P. Morris, Reg. No. 34,513

Michael P. Monis



PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to rest cond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/691,711 Filing Date INFORMATION DISCLOSURE 10/23/2003 Rolf BANHOLZER First Named Inventor STATEMENT BY APPLICANT Art Unit 1625 **Examiner Name** Janet L. COPPINS (Use as many sheets as necessary) Attorney Docket Number 1/1148-2-C2 1

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		^{US-} 6,506,900	01/14/2003	Banholzer, R. et al	
***************************************		^{US-} 4,042,700	08/16/1977	Banholzer, R. et al	
		^{US-} 4,608,377	08/26/1986	Banholzer, R. et al	
		^{US-} 4,783,534	11/08/1988	Banholzer, R. et al	
	 	^{US-} 5,654,314	08/05/1997	Banholzer, R. et al	
		^{US-} 5,770,738	06/23/1998	Banholzer, R. et al	
		^{US-} 5,952,505	09/14/1999	Banholzer, R. et al	
		^{US-} 6,486,321	11/26/2002	Banholzer, R. et al	
	I	US-			
		US-			
		US-			
	S 1	US-			
		US-			
		US-			
	1	US-			
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ (Number ⁴ (Kind Code ⁵ (# Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶					
***************************************	ļ					l					
***************************************	İ										

Examiner Signature			Date Considered	
		I DEED OOG B		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attaiched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				1			
Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/691,711		
INFO	RMATION DI	SCLO	SURE	Filing Date	10/23/2003		
STAT	EMENT BY	APPLI	CANT	First Named Inventor	Rolf BANHOLZER		
				Art Unit	1625		
(Use as many sheets as necessary)				Examiner Name	Janet L. COPPINS		
Sheet	2	of	2	Attorney Docket Number	1/1148-2-C2		

Examiner i Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T				
		U.S. Patent Application Publication No. 2003/0087927- Crystalline Anticholinergic, Processes for Preparing It and Its use for Preparing a Pharmaceutical Composition published May 8, 2003					
		U.S. Patent Application, Crystlline Micronisate, Process for the Manufacture thereof and use thereof for the Preparation of a Medicament, accorded Serial Number 10/385,175, filed March 10, 2003 for Docket No. 1/1310, Bender, H. et al					
		U.S. Patent Application HFA Suspension Formulations Containing Anticholinergic accorded Serial Number 10/392,559 filed March 20, 2003 for Docket No. 1/1316, Schmelzer, C.					
	••••••						
••••••	•••••						
•••••	**************						
			<u> </u>				
	/		1				

	 	-
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.